Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - William Blair boosted their FY2024 earnings per share (EPS) estimates for Tenaya Therapeutics in a report released on Wednesday, November 6th. William Blair analyst S. Corwin now forecasts that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.38). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.40) per share. William Blair also issued estimates for Tenaya Therapeutics' Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($1.58) EPS.
A number of other research analysts have also weighed in on the company. Leerink Partners reaffirmed an "outperform" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital dropped their price objective on Tenaya Therapeutics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday. Piper Sandler reaffirmed an "overweight" rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $14.75.
Read Our Latest Analysis on Tenaya Therapeutics
Tenaya Therapeutics Trading Down 6.9 %
Shares of Tenaya Therapeutics stock traded down $0.19 during trading hours on Monday, hitting $2.57. 6,093,492 shares of the company were exchanged, compared to its average volume of 773,638. Tenaya Therapeutics has a 1 year low of $1.61 and a 1 year high of $7.01. The business has a 50-day moving average of $2.04 and a 200-day moving average of $3.01. The stock has a market capitalization of $202.74 million, a price-to-earnings ratio of -1.78 and a beta of 2.34.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.07.
Insider Buying and Selling at Tenaya Therapeutics
In other Tenaya Therapeutics news, CEO Faraz Ali sold 9,748 shares of the company's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the sale, the chief executive officer now owns 188,331 shares of the company's stock, valued at approximately $544,276.59. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 19,539 shares of company stock valued at $56,468. Insiders own 32.76% of the company's stock.
Institutional Trading of Tenaya Therapeutics
A number of large investors have recently made changes to their positions in TNYA. abrdn plc purchased a new position in Tenaya Therapeutics during the third quarter worth about $1,063,000. Vanguard Group Inc. lifted its position in Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company's stock worth $14,973,000 after buying an additional 403,472 shares during the period. American Century Companies Inc. lifted its position in Tenaya Therapeutics by 27.7% during the second quarter. American Century Companies Inc. now owns 102,114 shares of the company's stock worth $317,000 after buying an additional 22,146 shares during the period. Dimensional Fund Advisors LP lifted its position in Tenaya Therapeutics by 42.5% during the second quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company's stock worth $316,000 after buying an additional 30,446 shares during the period. Finally, Algert Global LLC purchased a new position in Tenaya Therapeutics during the second quarter worth about $74,000. Institutional investors and hedge funds own 90.54% of the company's stock.
About Tenaya Therapeutics
(
Get Free Report)
Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.
Further Reading
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
